Merrimack Pharmaceuticals to Present at the 2010 UBS Global Life Sciences Conference
Merrimack Pharmaceuticals will present at the the 2010 UBS Global Life Sciences Conference in New York City on Monday, September 20, 2010 at 11:30am, EST.
Cambridge, MA (Vocus) September 14, 2010
Merrimack Pharmaceuticals today announced that it will present at the 2010 UBS Global Life Sciences Conference in New York City. Robert Mulroy, President and Chief Executive Officer, will provide a company overview at 11:30am, EST, Monday, September 20, 2010 at the Grand Hyatt in New York City, New York.
About Merrimack
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack has three oncology candidates in clinical development: MM-121, partnered with sanofi-aventis, in Phase 2 clinical testing, MM-111 in Phase 1/2 clinical testing, MM-398, partnered with PharmaEngine, Inc., in Phase 2 clinical testing and multiple pre-clinical development and research stage programs in the pipeline. MM-121, MM-111, and MM-398 are investigational drugs and have not been approved by the U. S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www. merrimackpharma. com.
Contacts
Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli(at)merrimackpharma(dot)com, http://www. merrimackpharma. com
Betsy Raymond Stevenson, RaymondStevenson Healthcare Comms, 860-984-1424, betsy(at)raymondstevenson(dot)com
# # #
